Rockwell Medical Inc has a consensus price target of $7 based on the ratings of 2 analysts. The high is $9 issued by HC Wainwright & Co. on May 16, 2024. The low is $5 issued by Maxim Group on October 5, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on May 16, 2024, March 25, 2024, and November 15, 2023, respectively. With an average price target of $9.67 between HC Wainwright & Co., there's an implied 398.28% upside for Rockwell Medical Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/16/2024 | Buy Now | 363.92% | HC Wainwright & Co. | Raghuram Selvaraju | → $9 | Reiterates | Buy → Buy | Get Alert |
03/25/2024 | Buy Now | 363.92% | HC Wainwright & Co. | Raghuram Selvaraju | $11 → $9 | Maintains | Buy | Get Alert |
11/15/2023 | Buy Now | 467.01% | HC Wainwright & Co. | Raghuram Selvaraju | → $11 | Reiterates | Buy → Buy | Get Alert |
10/05/2023 | Buy Now | 157.73% | Maxim Group | Anthony Vendetti | → $5 | Initiates | → Buy | Get Alert |
10/04/2023 | Buy Now | 467.01% | HC Wainwright & Co. | Raghuram Selvaraju | → $11 | Reiterates | Buy → Buy | Get Alert |
09/28/2023 | Buy Now | 467.01% | HC Wainwright & Co. | Raghuram Selvaraju | → $11 | Reiterates | Buy → Buy | Get Alert |
08/15/2023 | Buy Now | 467.01% | HC Wainwright & Co. | Raghuram Selvaraju | → $11 | Reiterates | Buy → Buy | Get Alert |
07/17/2023 | Buy Now | 467.01% | HC Wainwright & Co. | Raghuram Selvaraju | $9 → $11 | Maintains | Buy | Get Alert |
05/30/2023 | Buy Now | 363.92% | HC Wainwright & Co. | Raghuram Selvaraju | $7 → $9 | Maintains | Buy | Get Alert |
05/02/2023 | Buy Now | 260.82% | HC Wainwright & Co. | Raghuram Selvaraju | → $7 | Reiterates | → Buy | Get Alert |
04/04/2023 | Buy Now | 260.82% | HC Wainwright & Co. | Raghuram Selvaraju | → $7 | Reiterates | → Buy | Get Alert |
02/13/2023 | Buy Now | 260.82% | HC Wainwright & Co. | Raghuram Selvaraju | → $7 | Reiterates | → Buy | Get Alert |
02/08/2023 | Buy Now | 260.82% | HC Wainwright & Co. | Raghuram Selvaraju | $8 → $7 | Maintains | Buy | Get Alert |
08/30/2022 | Buy Now | 312.37% | HC Wainwright & Co. | Raghuram Selvaraju | $3 → $8 | Maintains | Buy | Get Alert |
01/18/2022 | Buy Now | 54.64% | HC Wainwright & Co. | Raghuram Selvaraju | $55 → $33 | Maintains | Buy | Get Alert |
09/07/2021 | Buy Now | 157.73% | HC Wainwright & Co. | Raghuram Selvaraju | — | Maintains | Buy | Get Alert |
The latest price target for Rockwell Medical (NASDAQ:RMTI) was reported by HC Wainwright & Co. on May 16, 2024. The analyst firm set a price target for $9.00 expecting RMTI to rise to within 12 months (a possible 368.75% upside). 7 analyst firms have reported ratings in the last year.
The latest analyst rating for Rockwell Medical (NASDAQ:RMTI) was provided by HC Wainwright & Co., and Rockwell Medical reiterated their buy rating.
There is no last upgrade for Rockwell Medical
There is no last downgrade for Rockwell Medical.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rockwell Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rockwell Medical was filed on May 16, 2024 so you should expect the next rating to be made available sometime around May 16, 2025.
While ratings are subjective and will change, the latest Rockwell Medical (RMTI) rating was a reiterated with a price target of $9.00 to $9.00. The current price Rockwell Medical (RMTI) is trading at is $1.92, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.